person · Reporting owner

FIELDS HEIDI

Disclosed activity across 5 companies

Tapewire entity: 45416
SEC CIK: 0001014330

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AGILENT TECHNOLOGIES, INC.A · Entity 3062	Director	March 14, 2025	March 18, 2025
AVANOS MEDICAL, INC.AVNS · Entity 28189	Director	January 04, 2021	January 06, 2021
Phathom Pharmaceuticals, Inc.PHAT · Entity 5177	Director	May 19, 2026	May 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AGILENT TECHNOLOGIES, INC.

Report date March 14, 2025 · Filed March 18, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectHeidi K. Fields Living Trust	58,851.252	Reported balance After 2025-03-14 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-03-14 · Grant · Acquired 1,819 · Balance 58,851.252 F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2: 378.588 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant.

F2: 378.588 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock.

F3: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee.

AVANOS MEDICAL, INC.

Report date January 04, 2021 · Filed January 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,855	Reported balance After 2021-01-04 transaction · row 1 1 source row Row 1 · 2021-01-04 · Grant · Acquired 4,005 · Balance 28,855 F1: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan.

Phathom Pharmaceuticals, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	54,122	Reported balance After 2026-05-19 transaction · row 1 1 source row Row 1 · 2026-05-19 · Grant · Acquired 24,122 · Balance 54,122 F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Financial Engines, Inc.

Report date July 19, 2018 · Filed July 23, 2018

Section 16 reporting ended · disclosed 2018-07-23. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-07-19 transaction · row 1 1 source row Row 1 · 2018-07-19 · Disposition to issuer · Disposed 21,290 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2018, by and among Financial Engines, Inc. (the "Company"), Edelman Financial, L.P., (the "Parent"), and Flashdance Merger Sub, Inc. ("Merger Sub"), a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on May 2, 2018, pursuant to which the Company became a wholly-owned subsidiary of Parent (the "Merger") on July 19, 2018 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Company was cancelled and converted into the right to receive $45.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-07-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-07-19 · Disposition to issuer · Disposed 1,224 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-07-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-19 · Disposition to issuer · Disposed 2,517 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-07-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-07-19 · Disposition to issuer · Disposed 2,567 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2018-07-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-07-19 · Disposition to issuer · Disposed 4,482 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.51	Direct	Reported balance After 2018-07-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-19 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75	Direct	Reported balance After 2018-07-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.17	Direct	Reported balance After 2018-07-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-07-19 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2018, by and among Financial Engines, Inc. (the "Company"), Edelman Financial, L.P., (the "Parent"), and Flashdance Merger Sub, Inc. ("Merger Sub"), a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on May 2, 2018, pursuant to which the Company became a wholly-owned subsidiary of Parent (the "Merger") on July 19, 2018 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Company was cancelled and converted into the right to receive $45.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes.

F2: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock.

F3: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable.

F4: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration.

Icosavax, Inc.

Report date February 19, 2024 · Filed February 21, 2024

Section 16 reporting ended · disclosed 2024-02-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-19 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2024-02-19 · Other · Disposed 11,376 · Balance 0 F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-19 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2024-02-19 · Disposition to issuer · Disposed 2,917 · Balance 0 F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.25	Direct	Reported balance After 2024-02-19 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-19 · Disposition to issuer · Disposed 22,278 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44	Direct	Reported balance After 2024-02-19 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-19 · Disposition to issuer · Disposed 25,266 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89	Direct	Reported balance After 2024-02-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-19 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.

F2: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2026 Filed May 21, 2026 20:30 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	24,122	$0.00	$0.00	Disclosure SEC source: 0001193125-26-234567 · ownership.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,122 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 19, 2026, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:56 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $4.95	$0.00	Disclosure SEC source: 0000950170-25-082453 · ownership.xml · derivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-02 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
June 03, 2025 Filed Jun 5, 2025 20:56 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	10,500	$0.00	$0.00	Disclosure SEC source: 0000950170-25-082453 · ownership.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 3, 2025, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
March 14, 2025 Filed Mar 18, 2025 14:00 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	1,819	$121.18	$220,426.42	Disclosure SEC source: 0001127602-25-009722 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 58,851.252 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 378.588 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
May 23, 2024 Filed May 24, 2024 23:43 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $10.30	$0.00	Disclosure SEC source: 0000950170-24-064826 · ownership.xml · derivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2034-05-22 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
May 23, 2024 Filed May 24, 2024 23:43 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	10,500	$0.00	$0.00	Disclosure SEC source: 0000950170-24-064826 · ownership.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 23, 2024, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
March 15, 2024 Filed Mar 19, 2024 22:23 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	1,678	$147.48	$247,471.44	Disclosure SEC source: 0001127602-24-010684 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 56,653.664 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · ownership.nature: Shares held in the Heidi K. Fields Living Trust. Read SEC document
March 05, 2024 Filed Mar 7, 2024 15:38 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	1,658	$144.34	$239,315.72	Disclosure SEC source: 0001127602-24-008947 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 54,975.664 F1 · balance_after: 412.072 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F2 · ownership.nature: Shares held in the Heidi K. Fields Living Trust. Read SEC document
February 19, 2024 Filed Feb 21, 2024 00:48 UTC	Icosavax, Inc. ICVX · Entity 94107	Disposition to issuerStock Option (Right to Buy) · Derivative	17,000	Not disclosed Strike: $9.89	Not disclosed	Disclosure SEC source: 0000950170-24-017415 · ownership.xml · derivative · entry 5 FIELDS HEIDI · CIK 0001014330 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document
February 19, 2024 Filed Feb 21, 2024 00:48 UTC	Icosavax, Inc. ICVX · Entity 94107	Disposition to issuerStock Option (Right to Buy) · Derivative	25,266	Not disclosed Strike: $7.44	Not disclosed	Disclosure SEC source: 0000950170-24-017415 · ownership.xml · derivative · entry 4 FIELDS HEIDI · CIK 0001014330 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,266 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document
February 19, 2024 Filed Feb 21, 2024 00:48 UTC	Icosavax, Inc. ICVX · Entity 94107	Disposition to issuerStock Option (Right to Buy) · Derivative	22,278	Not disclosed Strike: $6.25	Not disclosed	Disclosure SEC source: 0000950170-24-017415 · ownership.xml · derivative · entry 3 FIELDS HEIDI · CIK 0001014330 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,278 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time. Read SEC document
February 19, 2024 Filed Feb 21, 2024 00:48 UTC	Icosavax, Inc. ICVX · Entity 94107	Disposition to issuerCommon Stock	2,917	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-017415 · ownership.xml · nonDerivative · entry 2 FIELDS HEIDI · CIK 0001014330 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. F2 · price: Represents restricted stock units ("RSUs"). Pursuant to the Merger Agreement, immediately prior to the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive the Offer Price, subject to the terms of the Merger Agreement. Read SEC document
February 19, 2024 Filed Feb 21, 2024 00:48 UTC	Icosavax, Inc. ICVX · Entity 94107	OtherCommon Stock	11,376	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-017415 · ownership.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent. Read SEC document
June 06, 2023 Filed Jun 8, 2023 20:41 UTC	Icosavax, Inc. ICVX · Entity 94107	GrantStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $9.89	$0.00	Disclosure SEC source: 0001209191-23-035448 · doc4.xml · derivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 6, 2023, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
May 25, 2023 Filed May 30, 2023 22:53 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $11.72	$0.00	Disclosure SEC source: 0001209191-23-033013 · doc4.xml · derivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-24 F2 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
May 25, 2023 Filed May 30, 2023 22:53 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantCommon Stock	9,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-033013 · doc4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 F1 · shares: The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
March 16, 2023 Filed Mar 21, 2023 01:35 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	1,658	$136.82	$226,847.56	Disclosure SEC source: 0000899243-23-009213 · doc4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 56,221.592 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 79.447 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · ownership.nature: Shares held in the Heidi K. Fields Living Trust. Read SEC document
November 23, 2022 Filed Nov 28, 2022 20:47 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	3,635	$155.84	$566,482.04	Disclosure SEC source: 0001127602-22-026417 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 54,484.145 F1 · balance_after: Includes 269.453 shares acquired under the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F2 · ownership.nature: Shares held in the Heidi K. Fields Living Trust. Read SEC document
June 10, 2022 Filed Jun 14, 2022 21:01 UTC	Icosavax, Inc. ICVX · Entity 94107	GrantStock Option (Right to Buy)) · Derivative	22,278	$0.00 Strike: $6.25	$0.00	Disclosure SEC source: 0001209191-22-036740 · doc4.xml · derivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,278 Underlying: Common Stock · 22,278 shares Expires 2032-06-09 F2 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 10, 2022, the vesting commencement date, provided if the next occurring annual meeting of the Issuer's stockholders occurs prior to the full vesting of the option, any remaining options will vest on the date of such annual meeting, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document
June 10, 2022 Filed Jun 14, 2022 21:01 UTC	Icosavax, Inc. ICVX · Entity 94107	GrantCommon Stock	5,543	$0.00	$0.00	Disclosure SEC source: 0001209191-22-036740 · doc4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,293 F1 · shares: Represents restricted stock units ("RSUs") which will vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date. Read SEC document
May 25, 2022 Filed May 27, 2022 20:43 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $7.40	$0.00	Disclosure SEC source: 0001209191-22-032581 · doc4.xml · derivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-05-24 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
March 17, 2022 Filed Mar 21, 2022 21:08 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	1,785	$136.82	$244,223.70	Disclosure SEC source: 0001127602-22-010051 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 57,849.692 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: 297.073 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. The reporting person has elected to defer these shares of common stock. F3 · ownership.nature: Shares held in the Heidi K. Fields Living Trust. Read SEC document
July 30, 2021 Filed Aug 3, 2021 01:25 UTC	Icosavax, Inc. ICVX · Entity 94107	GrantCommon Stock	8,750	$15.00	$131,250.00	Disclosure SEC source: 0000899243-21-031146 · doc4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 F1 · shares: Represents restricted stock units ("RSUs") granted on July 30, 2021, 1/3 of the total number of RSUs granted vest on each of the first three anniversaries of May 29, 2021, the vesting commencement date, subject to the reporting person's continued service on the applicable vesting date. Vesting of the RSUs shall accelerate upon a Change of Control (as defined in the Icosavax, Inc. 2021 Incentive Award Plan). Each RSU represents a contingent right to receive one share of common stock of the Issuer. Read SEC document
May 21, 2021 Filed May 24, 2021 21:55 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $35.49	$0.00	Disclosure SEC source: 0001209191-21-035482 · doc4.xml · derivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date. Read SEC document
March 18, 2021 Filed Mar 22, 2021 19:21 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	1,850	$121.59	$224,947.05	Disclosure SEC source: 0001127602-21-011655 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Heidi K. Fields Living Trust Disclosed balance after: 55,767.619 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · balance_after: Number of shares reflects transfer of 53,508.641 shares from direct holdings to the Heidi K. Fields Living Trust. F3 · balance_after: 278.897 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. F4 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
January 04, 2021 Filed Jan 6, 2021 15:23 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,005	$0.00	$0.00	Disclosure SEC source: 0001606498-21-000004 · wf-form4_160994662474430.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,855 F1 · shares: Represents restricted share units issued to the reporting person on January 4, 2021 pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
June 04, 2020 Filed Jun 8, 2020 18:08 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	10,392	$91.00	$945,661.61	Disclosure SEC source: 0001127602-20-019102 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 0 F1 · price: The weighted average sale price was $90.999 with a range of $90.98 to $91.04. F2 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
June 04, 2020 Filed Jul 31, 2020 19:34 UTC Amendment	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	10,392	$91.00	$945,661.61	Disclosure SEC source: 0001127602-20-022400 · form4a.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 130.081 F1 · price: The weighted average sale price was $90.999 with a range of $90.98 to $91.04. F2 · balance_after: 130.081 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. F3 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
May 21, 2020 Filed May 22, 2020 21:03 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Options · Derivative	10,000	$0.00 Strike: $36.85	$0.00	Disclosure SEC source: 0001209191-20-031800 · doc4.xml · derivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-20 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Heidi Kunz continuing in service on the Board through such vesting date. Read SEC document
April 17, 2020 Filed Apr 21, 2020 23:40 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	3,081	$73.01	$224,940.73	Disclosure SEC source: 0001127602-20-014246 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 10,392 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. F2 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
January 02, 2020 Filed Jan 8, 2020 21:21 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	5,293	$0.00	$0.00	Disclosure SEC source: 0001606498-20-000008 · wf-form4_157851849629976.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,850 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2020 pursuant to the Avanos Medical, Inc. Outside Director's Compensation Plan. Read SEC document
September 20, 2019 Filed Sep 24, 2019 20:44 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	4,000	$78.56	$314,256.40	Disclosure SEC source: 0001127602-19-029024 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 7,311 F1 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions ranging from $78.5622 and $78.575, inclusive. The reporting person undertakes to provide to Agilent Technologies, Inc., any security holder of Agilent Technologies, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · ownership.nature: Shares held by the Heidi K. Fields Living Trust of which Ms. Kunz is a trustee. Read SEC document
August 30, 2019 Filed Sep 4, 2019 22:06 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	200	$70.98	$14,195.00	Disclosure SEC source: 0001127602-19-027928 · form4.xml · nonDerivative · entry 4 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 11,311 Read SEC document
August 30, 2019 Filed Sep 4, 2019 22:06 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	200	$70.97	$14,194.20	Disclosure SEC source: 0001127602-19-027928 · form4.xml · nonDerivative · entry 3 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 11,511 Read SEC document
August 30, 2019 Filed Sep 4, 2019 22:06 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	500	$70.97	$35,485.00	Disclosure SEC source: 0001127602-19-027928 · form4.xml · nonDerivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 11,711 Read SEC document
August 30, 2019 Filed Sep 4, 2019 22:06 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	3,100	$70.96	$219,981.58	Disclosure SEC source: 0001127602-19-027928 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 12,211 Read SEC document
March 21, 2019 Filed Mar 22, 2019 18:25 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	GrantCommon Stock	2,823	$82.00	$231,486.00	Disclosure SEC source: 0001127602-19-012823 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Living Trust Disclosed balance after: 15,311 F1 · shares: Shares acquired from award of Agilent Technologies, Inc. common stock for Non-Employee Directors that are fully vested upon grant. Read SEC document
January 02, 2019 Filed Jan 4, 2019 13:28 UTC	AVANOS MEDICAL, INC. AVNS · Entity 28189	GrantCommon Stock	4,248	$0.00	$0.00	Disclosure SEC source: 0001606498-19-000001 · wf-form4_154660849780366.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,557 F1 · shares: Represents restricted share units issued to the reporting person on January 2, 2019, pursuant to the Avanos Medical, Inc. Outside Directors' Compensation Plan. Read SEC document
September 11, 2018 Filed Sep 13, 2018 13:44 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	Exercise / conversionNon-Employee Director Stock Option (right to buy) · Derivative	5,482	$0.00 Strike: $13.89	$0.00	Disclosure SEC source: 0001127602-18-027493 · form4.xml · derivative · entry 4 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,482 shares Expires 2018-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 1999 Non-Employee Director Stock Plan. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document
September 11, 2018 Filed Sep 13, 2018 13:44 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	SaleCommon Stock	5,482	$67.73	$371,295.86	Disclosure SEC source: 0001127602-18-027493 · form4.xml · nonDerivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,802.494 Read SEC document
September 11, 2018 Filed Sep 13, 2018 13:44 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	Exercise / conversionCommon Stock	5,482	$13.89	$76,144.98	Disclosure SEC source: 0001127602-18-027493 · form4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,284.494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 120.041 shares were acquired through the Agilent Technologies, Inc. dividend reinvestment plan. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $27.17	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 8 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · derivative.exercise_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. F4 · derivative.expiration_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $8.75	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 7 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed F4 · derivative.exercise_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. F4 · derivative.expiration_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $6.51	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 6 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. F4 · derivative.expiration_date: At the Effective Time, each outstanding option to acquire shares of common stock of the Company became fully vested (to the extent unvested) and was cancelled and converted into the right to receive the product of (1) the excess, if any, of the Merger Consideration over the applicable exercise price of such option, multiplied by (2) the total number of shares of common stock of the Company subject to such option, subject to applicable withholding taxes. Any options that had an exercise price per share that was equal to or greater than the Merger Consideration were cancelled for no consideration. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerRestricted Stock Units · Derivative	4,482	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 5 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,482 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerRestricted Stock Units · Derivative	2,567	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 4 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,567 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerRestricted Stock Units · Derivative	2,517	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 3 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,517 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerRestricted Stock Units · Derivative	1,224	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · derivative · entry 2 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,224 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Financial Engines, Inc. common stock. F3 · derivative.exercise_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. F3 · derivative.expiration_date: At the Effective Time, each outstanding restricted stock unit award became fully vested and was cancelled and converted into the right to receive the Merger Consideration in respect of each vested share of common stock of the Company subject to such award, in each case subject to withholding taxes if applicable. Read SEC document
July 19, 2018 Filed Jul 23, 2018 18:12 UTC	Financial Engines, Inc. FNGN · Entity 164820	Disposition to issuerCommon Stock	21,290	$45.00	$958,050.00	Disclosure SEC source: 0001209191-18-043585 · doc4.xml · nonDerivative · entry 1 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2018, by and among Financial Engines, Inc. (the "Company"), Edelman Financial, L.P., (the "Parent"), and Flashdance Merger Sub, Inc. ("Merger Sub"), a copy of which is filed as Exhibit 2.1 to the Company's Form 8-K filed with the SEC on May 2, 2018, pursuant to which the Company became a wholly-owned subsidiary of Parent (the "Merger") on July 19, 2018 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Company was cancelled and converted into the right to receive $45.00 in cash, (the "Merger Consideration") without interest and subject to applicable withholding taxes. Read SEC document
June 11, 2018 Filed Jun 13, 2018 21:50 UTC	AGILENT TECHNOLOGIES, INC. A · Entity 3062	Exercise / conversionNon-Employee Director Stock Option (right to buy) · Derivative	5,000	$0.00 Strike: $13.89	$0.00	Disclosure SEC source: 0001127602-18-020818 · form4.xml · derivative · entry 4 FIELDS HEIDI · CIK 0001014330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,482 Underlying: Common Stock · 5,000 shares Expires 2018-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Right to buy Agilent Technologies, Inc. common stock granted under the Agilent Technologies, Inc. 1999 Non-Employee Director Stock Plan. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.